<DOC>
	<DOCNO>NCT02650271</DOCNO>
	<brief_summary>This study aim compare effect antiviral therapy entecavir lamivudine hepatitis B virus-related hepatocellular carcinoma radical hepatectomy . Included patient randomly divide two group .</brief_summary>
	<brief_title>Adjuvant Entecavir Postoperative HBV-HCC</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) associate poor prognosis , incidence increase dramatically many country . Hepatectomy radical therapy early-stage HCC . However , even radical resection , prognosis HCC patient remain discourage high recurrence rate frequent incidence intrahepatic metastasis . Therefore , prevent HCC recurrence important . Hepatitis B virus ( HBV ) infection major risk factor HCC development China . Some retrospective study show lamivudine entecavir treatment HBV-related HCC patient effectively reduce HCC recurrence rate increase survival rate hepatectomy . However , drug efficacy address .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Underwent open hepatic resection . Diagnosis HCC confirm histopathological examination surgical sample patient . HBsAg ( + ) . ChildPugh A liver function . AntiHCV ( + )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>adjuvant</keyword>
	<keyword>entecavir</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>hepatic resection</keyword>
</DOC>